New Delhi, 12th May 2021: Amid the second wave of Coronavirus disease (COVID19) in the country, the most concern is being raised about children. The reason for this is that till now only people above the age of 18 years are being given the vaccine dose. However, the US has yesterday approved the emergency use of a vaccine made for children in its country. Now its hope is also raised in India. Covaxin, prepared in collaboration with Bharat Biotech and ICMR, has been approved for trials for children from 2 years to 18 years.
According to reports, the trial is planned to be conducted among 525 participants at several locations. The hospitals include the All India Institute of Medical Sciences (AIIMS) Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur. The purpose of conducting the test would be to evaluate the Covaxin vaccine in children for safety, reactivity, and immunity. All these parameters are necessary to be approved for use in the general public.
An expert committee on Tuesday recommended clinical trials for the second/third stage of Bharat Biotech’s Covid-19 vaccine Covaxin for ages 2-18 years. Official sources have given this information. He said that this test will be done at various places including AIIMS in Delhi and Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Covid-19 Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO) on Tuesday discussed the application made by Bharat Biotech. It was requested to allow the second/third phase of the trial to assess, among other things, the enhancement of safety and immunity of Covaxin vaccine in children from two to 18 years.